Introduction
In recent years there has been increasing interest in the cardiovascular (CV) complications of chronic systemic inflammatory conditions such as rheumatoid arthritis (RA). It is now well recognised that RA is closely associated with the development of premature atherosclerosis resulting in high CV mortality and morbidity [1, 2] . Pathophysiological and epidemiological data suggest a clinically important relationship between RA and accelerated atherosclerosis as both conditions appear to be provoked by initial synovial/endothelial cell injury respectively [3] . However the mechanisms of vascular changes in RA remain partially understood with systemic inflammatory burden as well as classical cardiovascular disease (CVD) risk factors appearing to be pivotal in the initiation and progression of endothelial dysfunction [4, 5] . Over the last years the implication of genetic factors in the CVD risk has been studied with several studies reporting associations between gene variants such as tumour necrosis factor promoter polymorphism and atherosclerosis in RA patients [6] [7] [8] .
Endothelium-derived nitric oxide (NO) is a vasodilatory mediator with atheroprotective and anti-proliferative effects on the vascular wall. Constitutive production of NO is essential for the regulation of blood flow, the maintenance of vasorelaxation and the prevention of oxidative injury to the vascular endothelium [9] . Pro-inflammatory mediators and cytokines which are abundantly produced in RA exert numerous deleterious effects on the endothelial cells including a reduction in NO production, activation of endothelial cells and platelets, and derangement of fibrinolysis, all of which promote thrombosis and atherosclerosis. Impairment of NO synthesis is multifactorial but a growing body of evidence suggests that circulating inhibitors of NO synthase play a crucial role [10] . Assymetric dimethylarginine (ADMA) is an endogenous guanido-substituted analogue of L-arginine and decreases the bioavailability of NO by competing with L-Arginine at the active site of all the three isoforms M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 of NO synthase (NOS). ADMA is generated during proteolysis of various proteins containing methylated arginine residues, a procedure catalyzed by a group of enzymes referred to as protein-arginine methyl transferase's (PRMT's) [11] . Over the last decade ADMA has emerged as a novel biochemical marker of endothelial dysfunction and CV risk in various disease settings associated with atherosclerosis such as peripheral and coronal artery disease, lipid disorders, diabetes mellitus, insulin resistance, hypertension, chronic heart and renal failure [12, 13] as well as rheumatic diseases [14] . Several studies have demonstrated that plasma ADMA is an independent predictor for adverse cardiovascular events and death in patients with coronary artery disease [15] and in the general population [16] . Elevated ADMA levels have been reported in RA patients irrespective of the disease stage, the initiation and the type of treatment, the presence of clinical CVD or the detection of subclinical atherosclerosis in non-invasive assessments of endothelial function [17] [18] [19] [20] . In addition a handful of studies have assessed the impact of biologic disease modifying drugs on ADMA levels [21, 22] .
Dimethylarginine dimethylaminohydrolase (DDAH) is the key enzyme for the degradation of ADMA into citrulline and dimethylamine [23] . Over 90% of endogenous ADMA is hydrolyzed by DDAH with the remainder renally extracted. DDAH exists in two isoforms (DDAH1, DDAH2) encoded by different genes, with DDAH1 being primarily an enzyme of epithelial cells whereas DDAH2 is present in the vasculature [24] . Recent insights indicate that reduced DDAH activity occurs in several pathological conditions accompanied by excess CV morbidity and it is considered one of the crucial mechanisms responsible for ADMA accumulation and endothelial dysfunction. Both deleting the DDAH-1 gene in mice and inhibiting its activity through DDAH-specific inhibitors resulted in structural and functional endothelial changes, increased systemic vascular resistance and abnormal systemic blood pressure via ADMA mediated dysregulation of NO production [25, 26] . On the other hand M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 overexpression of DDAH in transgenic mice attenuates ADMA production and restores NO synthesis with favourable vascular outcomes such as reduced arterial stiffness, stabilisation of endothelial function and enhanced insulin sensitivity [27] . Functional variant of DDAH-2 gene is associated with chronic kidney disease and insulin sensitivity conditions linked with endothelial dysfunction and increased CVD risk [28, 29] . These observations underlie the important role of DDAH in the regulation of vascular homeostasis. Despite experimental data suggesting that DDAH1 is primarily responsible for the degradation of methylarginines [30] , the relative role of these isoforms in ADMA metabolism in humans remains unknown.
Derangement of DDAH/ADMA pathway has recently been described to participate in the pathogenesis of RA in a collagen-induced arthritis animal model [31] .
The aim of the present study was to determine whether DDAH1 and DDAH2 gene polymorphisms are associated with circulating ADMA in individuals with established RA.
Methods

Study population
Two-hundred and one consecutive RA patients were recruited from the rheumatology modifying anti-rheumatic drug (DMARD) use, oral prednisolone and anti-platelet agents. In addition, demographic information was collected by questionnaire. Insulin resistance was evaluated from fasting glucose and insulin using the Homeostasis Model Assessment of Insulin Resistance (HOMA) [33] .
Blood was collected from the patient's antecubital vein using a 23G butterfly needle (Greiner Bio One GmbH, Austria). All tests were carried out in the routine and research laboratories of Russells Hall Hospital, Dudley Group NHS Foundation Trust, UK and were analysed for routine laboratory biochemistry, lipids, haematology, Westergren erythrocyte sedimentation rate (ESR), and C-reactive protein. ADMA levels were measured in serum samples by using a commercial enzyme immunoassay ELISA kit (Immundiagnostik, Bensheim, Germany) as previously described [17] . The intra-assay (n=26) standard deviation was 0.031% and the inter-assay (n=6) standard deviation was 0.037%.
DDAH single nucleotide polymorphism (SNP) Genotyping
DNA Extraction
DNA was extracted from whole blood using the QuickGene-810 system. Blood was collected in EDTA-containing tubes, placed in an isolation vessel and the red cells were lysed. The white blood cells were then captured in a filter matrix and lysed so that the DNA was physically entrapped around the fibers. Isolated DNA was released from the matrix and 
Statistical analysis
Initially, ADMA levels were compared across the different classifications of the DDAH genes, namely minor allele, carrier and major allele, using one-way ANOVA models.
Multivariable general linear models were then used to account for potential confounding effects of factors which have previously been found to be associated with ADMA. These Post-hoc power calculations were performed for the comparisons of ADMA across the categories of each of the genes considered. As in the main analysis, separate calculations were performed using all of the data, and with the outliers excluded. In each case, pairwise comparisons were made between each combination of categories, based on independent samples t-tests. The alpha value was Bonferroni adjusted for 3 comparisons, hence a value of 1.67% was used. The minimal detectable differences for 80% power for each comparison were quoted (Supplementary material).
Results
Participant Characteristics
The demographic and disease-related characteristics for the RA patients are presented in Table 1 . One-hundred and twenty-two (61%) patients were receiving non-biologic DMARDS, fifty-one (25%) oral steroids, sixty (30%) biologic DMARDS, twenty nine (14%) non-steroidal anti-inflammatory drugs, seventy nine (39%) anti-hypertensive treatment and seventy four (37%) cholesterol-lowering agents.
Outliers
Three cases were identified as having unusually high ADMA measurements (>1.1 µmol/l), which became highly influential outliers in the statistical models. In order to ensure that the analysis was robust, the models were reproduced with these outliers excluded. The difference
between the models was generally small for the significant factors, but both models are quoted for each outcome for completeness. One-way ANOVA analysis did not reveal any statistically significant associations between serum ADMA concentrations and DDAH gene variants in our populations. These findings were similar in the analysis which excluded the three outliers (See Table 2 ). The data was also analyzed with ADMA concentrations divided into approximate tertiles (<0.5, 0.5-0.6 and >0/6 µmol/l). This gave results consistent with the ANOVA analysis, with no evidence of significant associations between gene categories and ADMA. (Table 3) 
Associations between ADMA and DDAH polymorphism
Multivariable Analysis
We investigated whether parameters of inflammation and insulin resistance, which have previously been linked with ADMA levels in RA, could have had a deleterious effect on the relationship between ADMA and gene expression. Multivariable general linear models were produced, which accounted for the effects of age, HOMA and ESR, in addition to gene expression, on ADMA. As with the previous analysis, separate models were produced for all patients, and with the outliers excluded (Table 4) .
ESR was consistently found to be associated with ADMA (p=0.001). However, after accounting for this relationship, as well as for the other potentially confounding factors in the model, the associations between the genotypes and ADMA remained non-significant.
Discussion
In this study we did not establish any significant association between circulating ADMA and SNPs in the DDAH1 and DDAH2 genes in patients with RA. DDAH genetic variants were not found to influence ADMA levels after adjustment for age, disease-related inflammation and insulin resistance parameters which have been previously linked with raised ADMA in this population. This is the first study of this kind to explore genetic variations in DDAH genes and their relationship with ADMA in RA patients.
A handful of studies have assessed the role of genetic variations of the DDAH1 and DDAH2 genes polymorphism and ADMA levels in humans [28, 29, 36, 37] . In diabetes mellitus, significant correlations between DDAH genes polymorphisms and ADMA levels were reported in patients with type 2 [38] but not type 1 [39] . Diabetes mellitus represents the prototypic disease carrying excessive risk for future CV events and similarly to RA, classical CVD risk factors are not sufficient to explain the increased incidence of CVD. In addition, clinical presentation and outcomes of coronary artery disease follow the same pattern in both conditions and currently the magnitude of CV risk in RA is considered equivalent and comparable to that of diabetes [40] . ADMA is elevated in patients with diabetes [41] and is associated with insulin resistance [42] while overexpression of DDAH appears to normalise hyperglycaemic profile in rats by enhancing insulin sensitivity [43] . It is worth noting that insulin resistance has been described as an independent predictor of high ADMA in patients with RA [44] and hypertension [13] , providing further support for the link between Evidence for ADMA accumulation in RA is wide ranging and its role in mediating endothelial dysfunction and accelerated atherosclerosis has been the focus of several publications. ADMA has been associated with morphological and functional parameters of subclinical vascular disease in some [18] but not all the studies assessing vascular morphology [45] , coronary microvascular perfusion [46] and in vivo endothelium-dependent and -independent microvascular and macrovascular function [17] . Higher mortality rates in RA in comparison with the general population are largely attributable to CVD, predominantly coronary atherosclerosis. Disruption of NO synthesis is crucial in the pathogenesis of endothelial dysfunction, so the recognition of the regulators of NO activity will help to provide a better understanding of the precise mechanisms involved and may also indicate potential therapeutic targets. As a growing amount of evidence suggests that ADMA levels predict future CV events and outcomes in retrospective cohort studies in the general population [16] and patients with established CVD risk factors [47] -which are highly prevalent in RA -endogenous mechanisms that regulate ADMA and NO bioavailability in RA are of great interest.
Several pathways incorporating increased formation and diminished hydrolysis are involved in the high circulating levels of ADMA in RA. The activation of the PRMT's and the augmentation of protein arginine type I N-methyltransferase by increased release of reactive oxygen species in inflamed synovium result in upregulation of ADMA synthesis [48] .
However it appears that the most important parameter in ADMA accumulation is DDAH dysfunction [49] . This enzyme seems to be extremely sensitive to oxidative stress and highlevels of NO production following overexpression of inducible NOS, nitrosates DDAH and with traditional and non-traditional CVD risk factors as well as autoantibodies in RA [55], it may represent an attractive marker for CVD risk stratification in this population. We performed a genetic association study to assess the potential contribution of polymorphic variants of DDAH genes to elevated ADMA levels in RA which yielded negative results.
Although we cannot exclude the possibilities that untyped SNPs in the current study may have an impact on ADMA levels or that none of the SNPs assessed are of functional importance for ADMA metabolism, it appears that ADMA concentration in RA is dependent on a variety of parameters other than DDAH activity which are involved in endothelial dysfunction in RA.
We performed our study in a well-defined, real-life RA population with detailed clinical and laboratory characterisization. We acknowledge that the major limitation of our study is the relatively small size of our cohort which cannot draw definite conclusions regarding the genetic basis of enhanced ADMA production in RA. However out study was sufficiently powered as according to post hoc power calculations the minimal detectable differences in ADMA levels between groups were consistently less than 0.1 µmol/l. It is worth noting that three patients with unusually high ADMA levels had similar genetic profile with reduced expression for rs2474123 SNP in DDAH1 gene and increased expression for the other polymorphism. The inclusion of these patients in the analysis did not change the results, but this observation may suggest that genetic control of ADMA may occur in patients with more severe disruption of endothelial function.
In conclusion, no evidence was found to suggest that genetic variation in DDAH1 and DDAH2 genes is significantly associated with serum ADMA levels in patients with RA.
There is still inadequate understanding of the production of ADMA in RA and its role in promoting atherosclerosis and contributing to CV morbidity and mortality in this population.
The complexity of CVD and the risk factor interactions requires further studies to investigate • ADMA is an endogenous inhibitor of NO and an emerging risk factor for endothelial dysfunction • ADMA levels are increased in RA but the mechanisms responsible for this remain to be determined • DDAH genes variants investigated in this study do not appear to influence ADMA levels in our population of RA patients.
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Supplementary table -Power calculation: minimal detectable differences
Quoted values are minimal detectable differences between groups from post-hoc power calculations, based on independent samples t-tests, with 80% power and 1.67% alpha. 
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